Incyte's Minjuvi Approved in Australia for Follicular Lymphoma – Incremental Positive, But No Thesis Change

What happened

Incyte announced that Minjuvi (tafasitamab), in combination with rituximab and lenalidomide, was approved in Australia for relapsed or refractory follicular lymphoma, positioning it as the first and only chemotherapy-free CD19/CD20 dual-targeted immunotherapy in that market. While the approval adds to the tafasitamab franchise's geographic expansion, Australia represents a modest revenue opportunity and does not materially alter the near-term financial outlook. The core investment thesis remains anchored on Incyte's ability to diversify away from Jakafi before its 2028 patent cliff, with Opzelura growth and U.S. tafasitamab uptake in DLBCL being far more consequential. The Australian approval provides a marginal tailwind but does not address the key risks of payer pressure on Opzelura or the timing of tafasitamab's first-line DLBCL filing. Investors should view this as a positive but low-impact milestone.

Implication

The approval supports Incyte's narrative of expanding its oncology portfolio, but Australia's contribution to tafasitamab sales will be small relative to the U.S. and EU. The stock's valuation already reflects high expectations for tafasitamab in larger markets; this news does not alleviate the core concern of Jakafi's 2028 patent cliff. Continue to monitor U.S. pediatric Opzelura uptake and tafasitamab sBLA timing for first-line DLBCL as more significant catalysts. Maintain cautious stance with attractive entry near $90.

Thesis delta

The Australian approval incrementally supports the tafasitamab franchise but does not change the bearish skew of the thesis. The primary diversification drivers (Opzelura growth, U.S. tafasitamab DLBCL approval) remain unproven at scale. The thesis still hinges on execution in larger markets and managing the Jakafi cliff; this news provides a slight positive but is insufficient to shift the potential sell rating.